Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
How Long Can This Top Stock Continue Defying the Bear Market?
12:45pm, Thursday, 17'th Nov 2022 The Motley Fool
It could only be the beginning for this pharma giant.
4 Reasons to Buy This Hybrid of a Growth and Income Stock
11:25am, Thursday, 17'th Nov 2022 The Motley Fool
This drugmaker's dividend yield is currently well above the average yield among S&P 500 stocks.
How Long Can This Top Stock Continue Defying the Bear Market?
07:45am, Thursday, 17'th Nov 2022
It could only be the beginning for this pharma giant.
4 Reasons to Buy This Hybrid of a Growth and Income Stock
06:25am, Thursday, 17'th Nov 2022
This drugmaker's dividend yield is currently well above the average yield among S&P 500 stocks.
Corcept (CORT) Up YTD on Robust Korlym Sales, Pipeline Advances
02:46pm, Wednesday, 16'th Nov 2022 Zacks Investment Research
Corcept's (CORT) Cushing's syndrome drug, Korlym, is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.
Eli Lilly (LLY) Stock Up 26.7% YTD: What's in Store for 2023?
01:46pm, Wednesday, 16'th Nov 2022 Zacks Investment Research
Lilly (LLY) expects to launch five new medicines by 2023-end, including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.
Benzinga
FTX Contagion Spreads To Hong Kong Exchange, At Risk Of Capital Deficit
Hong Kong-based global exchange AAX (AAB/USD) halted user withdrawals on Tuesday, saying it was at risk of a capital d
7 Value Stocks to Buy Before They Pop Off
03:25pm, Tuesday, 15'th Nov 2022
Despite the recent rebound of many U.S. stocks, the S&P 500 is still down 17% in 2022. It's also 8% below its Aug. high.
AstraZeneca's (AZN) 3 Cancer Drugs Get CHMP Nod for Expanded Use
03:09pm, Tuesday, 15'th Nov 2022 Zacks Investment Research
The CHMP recommends expanded use of AstraZeneca's (AZN) three key cancer drugs, Lynparza, Enhertu and Imfinzi.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
02:00pm, Tuesday, 15'th Nov 2022 Zacks Investment Research
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
10:32am, Tuesday, 15'th Nov 2022
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
AstraZeneca's (AZN) Imfinzi/Imjudo Combo Gets Another FDA Nod
07:10pm, Monday, 14'th Nov 2022 Zacks Investment Research
AstraZeneca (AZN) gets its second FDA approval for the Imfinzi+Imjudo combo in non-small cell lung cancer (NSCLC) indication.
The Zacks Analyst Blog Highlights Archer Daniels Midland, Charles River Associates, Murphy USA, Merck and New Fortress Energy
12:40pm, Monday, 14'th Nov 2022 Zacks Investment Research
Archer Daniels Midland, Charles River Associates, Murphy USA, Merck and New Fortress Energy are included in this Analyst Blog.
Merck, Nike Among 14 Companies To Announce Annual Dividend Increases In The Second Half Of November
10:37pm, Sunday, 13'th Nov 2022
There were a few double-digit boosts in the first half of November. Most notably, ADP came through with a 20% increase and Snap-On Tools with a 14% increase. Emerson extended its dividend growth strea
These 2 Dividend Paying ETFs Have A Track Record For Increasing Payments, Can Help Diversify Against Industry Risk
10:34pm, Friday, 11'th Nov 2022 Benzinga
Investing in an exchange-traded fund that invests in large cap dividend stocks can be a great way to secure passive income.
Additionally, investing in such an ETF will allow diversification of a por
